Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - TOP FLIGHT GAMEBIRDS, INC. | Financial_Report.xls |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20-549
FORM 10-Q/A
Amendment No. 1
(Mark One)
|
¨
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2011
or
|
¨
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
|
For the transition period from ______________ to _____________
Commission file number: 333-152286
GLOBAL PHARM HOLDINGS GROUP, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
20-8767223
|
|
|
(State or other jurisdiction of incorporation or
|
(I.R.S. Employer Identification No.)
|
|
|
organization)
|
||
|
25/F New World Center, No. 6009 Yitian Road, Futian
|
518026
|
|
|
District, Shenzhen,
|
(Zip Code)
|
|
|
People’s Republic of China
|
||
|
(Address of principal executive offices)
|
86-755-83230226
(Registrant’s telephone number, including area ccode)
Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ¨
|
Accelerated filer ¨
|
|
Non-accelerated filer ¨
|
Smaller reporting company þ
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No þ
As of August 31, 2011, there are 26,000,000 of $0.001 par value common stock issued and outstanding.
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) amends the quarterly report on Form 10-Q for the quarter ended June 30, 2011, originally filed on August 12, 2011 (the “Original Filing”), of Global Pharm Holdings Group, Inc. (the “Company”).
Pursuant to Rule 405(a)(2) of Regulation S-T, the Company is filing this Amendment No. 1 to submit its first Interactive Data File within the 30-day grace period provided thereunder. The sole purpose of this Amendment No. 1 is to include the Interactive Data File as Exhibit 101 hereunder.
This Amendment No. 1 contains a cover page, this explanatory note, a signature page and an exhibit index, including Exhibit 101.
PART II - OTHER INFORMATION
Item 6. Exhibits
Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.
|
Exhibit
Number
|
Description
|
|
|
10.1*
|
Credit Granting Maximum Amount Guarantee Contract of Legal Person, dated April 27, 2011, by and between Shandong Global Pharm and Jinan East Lishan Road Branch of Qilu Bank Co., Ltd.
|
|
|
10.2*
|
Credit Granting Contract of Legal Person, dated April 27, 2011, by and between Shandong Global Pharm and Jinan East Lishan Road Branch of Qilu Bank Co., Ltd.
|
|
|
10.3*
|
Mortgage Contract of Maximum Amount for Goods Control and Financing, dated April 27, 2011, by and between Shandong Global Pharm and Jinan East Lishan Road Branch of Qilu Bank Co., Ltd.
|
|
10.4*
|
Warehouse and Storage Supervision and Management Agreement, dated April 27, 2011, by and between Shandong Global Pharm and Jinan East Lishan Road Branch of Qilu Bank Co., Ltd. and Shandong Yayin Assets Management Co., Ltd.
|
|
|
10.5*
|
Lease Contract, dated March 1, 2009, by and between Taian Senlin Pharmaceutical Co., Ltd. and Dabaiyu Resident Committee
|
|
|
10.6*
|
Lease Contract, dated January 1, 2011, by and between Zibo Hongmao Pharmaceutical Co., Ltd. and Zibo Drug Purchasing & Supply Station of Shandong Province
|
|
|
10.7*
|
Lease Contract, dated May 20, 2011, by and between Anhui Sino-Green and Li Wanzhi
|
|
|
10.8*
|
Lease Contract, dated April 10, 2011, by and between Shandong Sino-Green and People’s Government of Mashan Town
|
|
|
10.9*
|
Land Transfer Agreement, dated April 29, 2011, by and between Shandong Sino-Green and Chanqging District, Mashan Town
|
|
|
10.10*
|
Land Transfer Contract, dated June 10, 2011, by and between Anhui Sino-Green and Shibali Town Government of Qiaocheng District, Bozhou City
|
|
|
10.11*
|
M&A Agreement dated May 25, 2011, by and between Shandong Global Pharm and Taian Senlin Pharmaceutical Co., Ltd.
|
|
|
10.11A*
|
Supplementary Agreement, dated May 25, 2011, by and between Shandong Global Pharm and Taian Senlin Pharmaceutical Co., Ltd.
|
|
|
10.12*
|
M&A Agreement dated May 25, 2011, by and between Shandong Global Pharm and Zibo Hongmao Pharmaceutical Sales Co., Ltd.
|
|
|
10.12A*
|
Supplementary Agreement, dated May 25, 2011, by and between Shandong Global Pharm and Zibo Hongmao Pharmaceutical Sales Co., Ltd.
|
|
|
10.13*
|
M&A Agreement, dated July 4, 2011, by and between Shandong Global Pharm and Bozhou Xinghe Pharmaceutical Co., Ltd.
|
|
|
10.13A*
|
Supplementary Agreement, dated July 5, 2011, by and between Shandong Global Pharm and Bozhou Xinghe Pharmaceutical Co., Ltd.
|
|
|
10.14*
|
Equity Transfer Agreement, dated May 25, 2011, by and between Shandong Global Pharm and Kong Lingjin (for Taian Senlin)
|
|
|
10.15*
|
Equity Transfer Agreement, dated May 25, 2011, by and between Shandong Global Pharm and Lv Xinjuan (for Taian Senlin)
|
|
|
10.16*
|
Equity Transfer Agreement, dated May 31, 2011, by and between Shandong Global Pharm and Chen Hongsheng (for Zibo Hongmao)
|
|
|
10.17*
|
Equity Transfer Agreement, dated July 4, 2011, by and between Shandong Global Pharm and Han Lingzhi (for Bozhou Xinghe)
|
|
|
10.18*
|
Equity Transfer Agreement, dated July 4, 2011, by and between Shandong Global Pharm and Gu Quanhui (for Bozhou Xinghe)
|
|
|
10.19*
|
Lease Contract, dated January 1, 2010, by and between Zibo Hongmao Pharmaceutical Co., Ltd. and Zibo Drug Purchasing & Supply Station of Shandong Province | |
|
31.1*
|
Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**
|
|
|
31.2*
|
Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**
|
|
32.1*
|
Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
|
|
|
32.2*
|
Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
|
|
| 101 |
The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, (ii) the Condensed Consolidated Statements of Income and Comprehensive Income for each of the three and six months ended June 30, 2011 and 2010, (iii) the Condensed Consolidated Statements of Cash Flows for each of the six months ended June 30, 2011 and 2010 and (iv) the Notes to the Condensed Consolidated Financial Statements.(1)
|
|
|
(1)
|
Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and otherwise are not subject to liability under those sections.
|
* Previously filed with Original Filing.
** The referenced exhibits marked by an “**” submitted with the Original Filing shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
SIGNATURES
In accordance with the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
GLOBAL PHARM HOLDINGS GROUP, INC.
|
||
|
Date: September 6, 2011
|
/s/ Yunlu Yin
|
|
|
Yunlu Yin
|
||
|
Chief Executive Officer and President
|
||
|
(Principal Executive Officer)
|
||
|
Date: September 6, 2011
|
/s/ An Fu
|
|
|
An Fu
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial Officer)
|